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Primary biliary cirrhosis (PBC) has been often coined a model autoimmune disease based on the
homogeneity amongst patients, the frequency and similarity of antimitochondrial antibodies, including
the highly directed immune response to pyruvate dehydrogenase (PDC-E2). A signiﬁcant number of
patients with PBC suffer from sicca and amongst these, there are patients who also have classic Sjögren’s
syndrome. Indeed, both PBC and Sjögren’s syndrome are characterized by inﬂammation of target
epithelial elements. Both diseases can be considered on the basis of a number of other related clinical
aspects, including proposed unique apoptotic features of the target tissue, the role of secretory IgA, and
the frequency with which both diseases overlap with each other. Indeed, PBC may be considered
a Sjögren’s syndrome of the liver, whereas Sjögren’s syndrome can be equally discussed as PBC of the
salivary glands. Dissection of the genetic predispositions for both diseases and especially the molecular
basis of effector mechanisms, will become critical elements in developing new therapies.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
The current view of autoimmunity is that there will be common
susceptibility backgrounds that apply to related pathologies, as
supported by the frequent coexistence of more than one autoim-
mune disease in the same patient, the female predominance [1,2],
and the similar genetic associations found within immune-related
genes [3,4], along with other common factors [5e7]. One major
example of this so-called autoimmune clustering is the coexistence
of Sjögren’s syndrome (SS) and primary biliary cirrhosis (PBC).
These two autoimmune diseases are characterized by the
progressive immune-mediated destruction of the epithelial tissues
of the salivary and lacrimal glands and the intra-hepatic bile ducts,
respectively.
The autoimmune destruction in SS primarily affects exocrine
glands and other organs [8] and in 1979 the term “autoimmune
exocrinopathy” was coined [9]. More recently, Moutsopoulos sug-
gested the term “autoimmune epithelitis” for the condition to
reﬂect the target of the immune-mediated injury [8]. The rheu-
matologist or clinical immunologist following patients with SS will
often be facing the possibility of encountering some degree of liverdicine, IRCCS Istituto Clinico
Italy. Tel.: þ39 2 8224 5129;
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main diagnosis and the prevalence varies among series and
depends on the case-ﬁnding criteria.
Earlier studies based on clinical ﬁndings and serology estimated
that liver abnormalities were found in 18e20% of SS cases to
include autoimmune liver diseases and chronic viral hepatitis [10]
while liver enlargement was reported during the examination in
2e20% of patients with SS [11e13]. This review will discuss the
common themes of PBC that relate to SS and attempt to underline
similarities with SS (Table 1) although we admit that numerous
peculiarities remain [14e16].
2. Primary biliary cirrhosis (PBC)
PBC is a chronic cholestatic liver disease characterized by the
immune-mediated destruction of the epithelial cells lining the
small and medium-sized intra-hepatic bile ducts with resulting
progressive ﬁbrosis [17]. The diagnosis of PBC is based on the
concomitant presence of two out of three internationally accepted
criteria [17], i.e. (i) elevation of biochemical indices of cholestasis
ee.g. alkaline phosphatase- for more than six months, (ii) the
presence of serum antimitochondrial antibody (AMA) at titers
exceeding 1:80, and (iii) consistent liver histology (Table 1). In some
cases a nuclear magnetic resonance cholangiography is necessary
to exclude the involvement of large bile ducts as in primary scle-
rosing cholangitis. In the past decade, the term “autoimmunes and Sjögren’s syndrome: Autoimmune epithelitis, Journal of Auto-
Table 1
Classiﬁcation criteria used for PBC and SS.
PBC [17] SS [31]
Clinical Fatigue
Pruritus (late stages)
Ocular and oral dry symptoms
for longer than 3 months
or use of tear substitute
more than 3 times a day
or recurrent need to drink
to swallow dry food
Histology and
functional
tests
Nonsuppurative cholangitis
with interlobular bile
duct injury at liver biopsy
Abnormal Schirmer’s or Rosa
Bengala test or lacrimal gland
biopsy with focus score >1
and abnormal sialometry
or salivary gland scintigraphy
or parotid sialography or
salivary gland biopsy with
focus score >1
Serum
markers
Serum AMA > 1:40 Anti-SSA or anti-SSB
PBC-speciﬁc ANA Rheumatoid factor
Serum alkaline phosphatase
> 1,5-fold the normal value
for more than 6 months
Speckled ANA
Table 2
Prevalence of serum autoantibodies observed in PBC and SS (highest rates are
reported).
PBC SS
Antinuclear Ab (ANA) 50% [19] 90% [150]
ANA pattern Rim-like Multiple nuclear dots Speckled
Antimitochondrial Ab (AMA) 95% [37] 5% [151]
Anticentromere Ab (ACA) 20% [152] 4% [153]
Anti-SSA/SSB 50% [154] 60% [150,155]
Rheumatoid factor 70% [156] 60% [150]
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but positive for serum antinuclear (ANA) and anti-smooth muscle
(SMA) serum antibody [18,19]. The ﬁnding that both the salivary
and lacrimal glands [20,21] as well as the urinary tract epithelium
could also be injured in PBC led the senior author of this article to
suggest that PBC, similar to SS, can be considered a generalized
epithelitis [22].3. Diagnostic criteria
Histology remains crucial when other diagnoses of liver disease
have to be ruled out, particularly in AMA-negative patients [23]
despite the new diagnostic tools [24e26]. The typical histological
lesion for PBC can be summarized as a chronic nonsuppurative
destructive cholangitis involving different cell types [27e29] tar-
geting small and medium interlobular bile ducts with a maximum
diameter 80 m. Liver histology and staging manifests a wide
sampling variability with four recognized stages ranging from
portal inﬂammation to the appearance of ﬁbrous septa between
adjacent portal tracts and ultimately cirrhosis. At advanced stages,
PBC cannot be discriminated from cirrhosis of other etiologies [30].
Early disease stages share numerous similarities with SS in which
exocrine glands are inﬁltrated by lymphocytes, mainly CD4þ,
interfering with the glandular function through the destruction of
glandular elements by cell-mediated mechanisms, cytokines that
activate pathways characterized by type 1 and 2 interferons,
autoantibodies against muscarinic receptors, and metal-
loproteinases that interfere with the interaction of the epithelium
with the extracellular matrix necessary for efﬁcient glandular
function [28,31].
Serum autoantibodies remain a crucial tool for diagnostic
purposes in rheumatology and this applies to both SS and PBC.
Nevertheless, there is limited overlapping in the autoantibody
proﬁles of these two conditions, as illustrated in Table 2, and
speciﬁc positivities retain their diagnostic power. It is well estab-
lished that patients with SS commonly have detectable serum anti-
Ro/SSA anti-La/SSB and anti-U1RNP [32], while PBC sera are char-
acterized by serum antimitochondrial antibody (AMA), possibly the
most speciﬁc autoantibody in clinical immunology [33]. AMA are
highly speciﬁc for PBC and can be detected in nearly 100% of
patients when sensitive diagnostic methodologies based on
recombinant antigens are used [34,35]. In most clinical settings,
however, indirect immunoﬂuorescence techniques are used forPlease cite this article in press as: Selmi C, et al., Primary biliary cirrhosi
immunity (2011), doi:10.1016/j.jaut.2011.11.005initial screening of cases and might provide falsely positive or
negative results. AMA are directed against components of the 2-oxo
acid dehydrogenase (2-OADC) family of enzymes within the mito-
chondrial respiratory chain [36], most frequently the E2 and E3-
binding protein (E3BP) components of the pyruvate dehydroge-
nase complex and the E2 components of the 2-oxo glutarate
dehydrogenase and branched-chain 2-oxo acid dehydrogenase
complexes. In all three antigens epitopes contain the motif DKA,
with lipoic acid covalently bound to the lysine (K) residue. The role
of lipoic acid in epitope recognition by AMA is unclear. The path-
ogenic role of AMA is debatable, since no clinical correlation can be
found and animal models developing serum AMA do not develop
PBC-like liver lesions.
Serum antinuclear antibodies (ANA) are frequently observed in
both conditions but with a higher prevalence in SS compared to
PBC. In PBC, these are more frequently of the multiple nuclear dot
or rim-like/membranous patterns and possibly more prevalent
among AMA-negative PBC patients [19,26,37,38]. The ﬁrst pattern is
produced by autoantibodies against gp210 and nucleoporin 62
within the nucleopore complex and the second pattern by auto-
antibodies against sp100, promyelocytic leukemia (PML) and small
ubiquitin-like modiﬁer (SUMO) proteins [39]. Antibodies against
gp210 are associated with a more rapidly progressing disease
[40e42], different from serum AMA. AMA are directed at the
pyruvate dehydrogenase complex (anti-PDC) and are routinely
screened with indirect immunoﬂuorescence. In a multicenter
study, AMAwere present in 22% of SS,17% of SLE,10% of rheumatoid
arthritis, and 10% of scleroderma sera [43]. Interestingly, SS per se or
associated with other autoimmune diseases increases the risk of
having positive serum AMA but data are burdened by the lack of
more speciﬁc recombinant antigens that were recently developed
[25,37].
4. Clinical features and management
The major clinical features of PBC and SS are compared in
Table 3. PBC at presentation is classically characterized by fatigue
and pruritus while physical ﬁndings may include skin hyperpig-
mentation and liver and spleen enlargement [17]. End-stage
symptoms are those of all types of liver cirrhosis, including
ascites, jaundice, hepatic encephalopathy, and upper digestive
bleeding. Fatigue is an incompletely deﬁned, nonspeciﬁc symptom
that affects up to 70% of patients with PBC and that is often over-
looked, particularly in middle-aged women. Importantly, the
severity of fatigue is independent of the stage of PBC or its other
features (pruritus or severe cholestasis), nor does it depend on
psychiatric factors. No medical treatment has been shown to be
effective in alleviating this symptom, although fatigue has never
been included as an endpoint in any of the large controlled clinical
trials [44e49]. As many as 70% of patients with PBC and jaundice
suffer from pruritus [50e53]. Longitudinal data show that the vast
majority of patients will eventually experience this symptom
during their lifetime; pruritus might long precede jaundice onsets and Sjögren’s syndrome: Autoimmune epithelitis, Journal of Auto-
Table 3
A comparison of the general features of PBC and SS.
PBC SS
Female/male
ratio
10:1 9:1
Mean age
at diagnosis
55 Bimodal (20, 50)
Disease target Bile duct, salivary gland
epithelia, and uroepithelium
Salivary gland, bile duct,
bronchial, alveolar, and
tubular epithelia
Environmental
factors
Bacteria, xenobiotics Putative viral infections
(EBV, retroviruses)
Epigenetics Different methylation in
hemidesmosome gene;
disease-speciﬁc miRNAs
in minor salivary glands
Different methylation
at X-linked promoters
Proteomics Possible serum biomarkers,
no liver tissue disease-speciﬁc
biomarkers
Proposed salivary
biomarkers
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warm climates. Despite remaining a challenging symptom, the use
of cholestyramine (4 g two or three times a day) ameliorates
pruritus while rifampicin has been used to achieve rapid symptom
relief; its prolonged use, however, should be avoided. Portal
hypertension is frequently found in patients with PBC and, impor-
tantly, may precede any other sign or symptom of liver cirrhosis.
Over half of untreated patients eventually develop portal hyper-
tension over a 4-year period while medical treatment slows the
development of this complication [54,55]; once varices are found,
the bleeding prevention or treatment are not different from other
chronic liver diseases. An accelerated bone loss is common in long-
standing cholestasis compared to sex- and age-matched healthy
individuals; this is referred to as metabolic bone disease secondary
to reduced bone deposition [56e58]. Current treatment of bone
loss includes oral calcium supplementation, weight-bearing
activity, and oral vitamin D replacement, if deﬁciency is found.
Postmenopausal hormone replacement therapy should be consid-
ered but jaundice and other signs of liver failure should be evalu-
ated during the ﬁrst months of treatment. Hyperlipidemia is
common in up to 85% of patients with PBC and both serum
cholesterol and triglyceride high levels can be observed [59e62];
accordingly, statins are usually not necessary but can be well
tolerated.
Autoimmune comorbidity is an important feature of PBC.
Various disorders, particularly other autoimmune syndromes, are
associated with PBC at various degrees [34,63e65]. Our 2005
nation-wide epidemiological study of 1032 patients with PBC re-
ported that one-third of cases are also affected by another auto-
immune disease, most commonly SS, Raynaud’s phenomenon,
autoimmune thyroid disease, scleroderma, and systemic lupus
erythematosus, while the prevalence of rheumatoid arthritis did
not differ from controls [66]. Interestingly, recent data demon-
strated that patients affected by both PBC and scleroderma
manifest a less aggressive liver disease, thus suggesting an active
interaction between the two conditions [67]; whether this applies
also to SS remains to be determined. The association of liver
involvement in SS with serum antimitochondrial antibodies (AMA)
was ﬁrst reported in 1970 [68] with studies on well documented
SS patient populations, observing a 5e10% antibody prevalence. On
one hand, about half of them have elevated liver enzymes while,
on the other hand, liver enzymes may be elevated without the
coexistence of AMA. According to several studies, characteristic
symptoms of SS such as dry mouth or dry eyes are commonly
(47e73%) found also in PBC. In addition, objective ﬁndings of dry
eyes or dry mouth (such as abnormal Schirmer test, or diminishedPlease cite this article in press as: Selmi C, et al., Primary biliary cirrhosi
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while radiological ﬁndings of sielectasia were demonstrated in 25%
of PBC cases. Furthermore, these frequently (26e93%) manifest
histological changes compatible with the diagnosis of SS at salivary
gland biopsies [12,69,70]. Nevertheless, these individuals differ
from the patients with primary SS. They rarely have serious
sequelae and their serological and immunogenetic features are not
identical to those observed in patients with primary SS. More
speciﬁc, in these patients anti-Ro autoantibodies are rarely
observed and the frequency of HLA-B8, -DR3 and DRW52 is lower
compared to patients with primary SS. Thus, SS complicating PBC
is considered similar to that occurring in RA patients (secondary
SS) [71].
5. Epidemiology and geoepidemiology
In both PBC and SS there is a striking female predominance and
female to male ratios as high as 10:1 for PBC and 9:1 for SS
[34,72,73]. For both conditions the age at diagnosis is in the mid-
50s; however, there are two age peaks of primary Sjögren’s
syndrome, with the ﬁrst after menarche during the 20s to 30s and
the second aftermenopause [31,74]. There is a signiﬁcant variability
in the reported prevalence of SS, ranging from 0.2 to 4.8% [75e82],
based on the different diagnostic criteria adopted, as illustrated in
Fig. 1.
Data about the incidence and prevalence of PBC have generally
been obtained through observational (rather than population-
based) studies and might not indicate true rates in the general
population. While there is general agreement on the simpler
diagnostic criteria compared to SS [17], regional differences could
vary on the basis of medical awareness and expertise [83]. Indeed,
a population-based approach to case detection has little feasibility
for PBC because of its rarity and the lack of non invasive tools for
most sensitive case-ﬁnding. As a result, reported prevalence ranges
from 6 to 402 cases per million (Fig. 1) [84e96]. By contrast, ﬁnd-
ings of serological studies with indirect immunoﬂuorescence in
large groups of unselected serum samples show that prevalence of
serum AMA in the general population can be as high as 0.5%, with
lower frequencies when blood donors are investigated [34].
Different from SS, the variability in the reported estimates of the
incidence and prevalence of PBC is likely secondary to different
case-ﬁnding methods, local physician awareness, and quality levels
of health-care systems, as suggested by the socioeconomical
differences [66]. On the basis of data from case-ﬁnding studies,
however, a latitudinal geoepidemiological pattern of occurrence of
primary biliary cirrhosis has been proposed, with the disease being
more prevalent in northern Europe and North America [97,98].
6. Genetics, epigenetics, and proteomics
Our knowledge of the genetics of SS and PBC remains largely
incomplete and is summarized in Table 4. PBC is more frequent in
relatives of affected individuals and the term ‘familial PBC’ has been
coined to indicate families that have more than one case. Our data
indicate 6% of cases have a ﬁrst-degree relative that is also affected
[66]. More importantly, the concordance rate observed among
monozygotic twins for PBC is 63%, amongst the highest reported in
autoimmunity, reinforcing the idea of an important role of genetics
in disease susceptibility [99]. Due to the rarity of the disease several
association studies have attempted to identify genes associated
with PBC although no family study of genetic linkage has been
performed. Associations are often not applicable to all populations
but suggest that a multi-hit genetic model seems to apply to PBC,
with different genetic variants conferring susceptibility (ﬁrst hit)
and others inﬂuencing disease progression (second hit) [98]. Thes and Sjögren’s syndrome: Autoimmune epithelitis, Journal of Auto-
Fig. 1. The worlwide map of PBC and SS geoepidemiology [75e96,159]. Prevalence rate (per million) are illustrated for major areas.
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produced associations that are often weak or limited to speciﬁc
geographical areas [100]. Following the numerous association
studies reported over the past decades for candidate genes in PBC,
the ﬁrst genome-wide caseecontrol association studies were re-
ported in 2009 and 2010 in patients and controls from Canada, the
US, and Italy and demonstrated signiﬁcant associations of PBC with
IL12A, IL12RB2, and STAT4 polymorphisms [101,102]. The impor-
tance of IL12 was most recently supported by data in a PBC animal
model that IL-12p40 is crucial to autoimmunity development thus
proving an ideal link between genomic studies and disease path-
ogenesis with potential therapeutic implications [103]. Further-
more, the growing ﬁeld of microRNA effects on immune
modulation has been investigated also in PBC where a speciﬁc
signature was described for the ﬁrst time [104]. Interestingly, this
was accompanied also by data obtained in SS [105,106] along with
other epigenetic evidence [107,108]. Of note, an age-dependent
enhanced monosomy X was reported in peripheral lymphocytes
of women with PBC [109] and scleroderma [110], thus suggesting
that PBC might ensue from a polygenic model with an X-linked
major locus of susceptibility in which genes escaping inactivation
are the major candidates [109,111] also based on the presence of
AMA in major X chromosome diseases [112].
Beside genetics, our epidemiological data demonstrated that
a high risk of developing PBC is associated with a history of urinaryTable 4
Proposed genetic factors involved in the etiology of PBC and SS. Data are gathered
from HLA studies and genome-wide association studies (GWAS) along with the
more recent epigenetic data.
PBC SS
HLA DR3, DR8, and DR4 in white,
DR2 and DR3 in Japanese,
DQA1*0102, and DQ/b1*0402
DR2, DR3
GWAS DQB1, IL12A, IL12RB2, STAT4,
IRF5, IKZF3/ORMDL3, SPIB
STAT4, IRF5
Epigenetics Different methylation in
hemidesmosome gene;
disease-speciﬁc miRNAs
in minor salivary glands
Different methylation
at X-linked promoters
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lifestyle factors, such as smoking, and previous pregnancies [66].
Experimental studies have focused on two main classes of agents
possibly triggering PBC: infectious (bacteria and viruses) and
chemical (xenobiotics) [113]. Most evidence has been reported for
Escherichia coli, while contrasting data have been obtained on the
role of Chlamydia pneumoniae [114]. Finally, we provided experi-
mental evidence suggesting that Novosphingobium aromaticivorans,
a ubiquitous xenobiotic-metabolizing Gram-negative bacterium, is
the best candidate yet for the induction of PBC [115]. In a comple-
mentary fashion, xenobiotics (i.e. foreign compounds that may
either alter or complex to deﬁned self or nonself proteins) have
been advocated to induce a change in themolecular structure of the
native protein sufﬁcient to induce an immune response. Such
immune responses may then result in the cross-recognition of the
self form, which could in turn perpetuate the immune response,
thus leading to chronic autoimmunity. Interestingly, most xenobi-
otics are metabolized in the liver, thereby increasing the potential
for liver-speciﬁc alteration of proteins [116].
Epigenetics is an emerging candidate link between genomics
and environment in generating phenotype variability and disease
susceptibility in adult life [117]. Alterations in the post-translational
modiﬁcation of histones and DNA methylation are the two major
epigenetic mechanisms that may potentially cause a breakdown of
immune tolerance and the perpetuation of autoimmune diseases as
well represented by the most recent data on the hyper-IgM
commonly associated with PBC [118]. Several studies both in clin-
ical settings and experimental models proposed that the epi-
genome may hold the key to a better understanding of
autoimmunity initiation and perpetuation. The impact of epige-
netic changes has been suggested in systemic lupus erythematosus,
rheumatoid arthritis, multiple sclerosis, in some cases based on
observations in animal models. Data on the epigenetics of PBC are
limited to one study from our group inwhich consistent differences
were observed in the DNA methylation proﬁle of two X-linked
genes (namely CLIC2 and PIN4) in peripheral lymphocytes from
discordant twins [119]. This paucity of data is reﬂected also in SS as
only most recently there have been reports of speciﬁc microRNAs
overexpressed in SS salivary glands [120]. Finally, recent effortss and Sjögren’s syndrome: Autoimmune epithelitis, Journal of Auto-
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for serum biomarkers of autoimmune diseases. This goal is partic-
ularly challenging in diseases such as PBC and SS in which liver and
minor salivary gland biopsies are still currently used diagnostic
tools. MALDI-TOF-MS combined with magnetic beads found in
serum of a Chinese cohort of PBC patients found 69 presumable
proteins and peptides speciﬁcally characterizing PBC [121] but an
independent conﬁrmation is awaited. More recently, an MS-based
study of PBC and control liver biopsies deﬁned a proteomic
proﬁle that characterizes PBC as well as other autoimmune liver
diseases [122]. We should note that similar approaches should be
encouraged in SS for which biological samples (i.e. saliva) can be
easily obtained.
7. Immunopathogenesis
In both PBC and SS serumautoantibodies (AMAand anti-Ro, anti-
La for PBC and SS respectively) [32,123e125] target ubiquitous
proteins expressed in all nucleated cells [126,127], as illustrated in
Fig. 2. Nevertheless, PBC and to a lesser degree SS are organ speciﬁc
diseases, indicating that epithelia (biliary epithelial cells and sali-
vary gland epithelial cells for PBC and SS respectively) are likely
active participants in the pathogenesis of the diseases [128]
(Table 5). First, a hypothesis based on the unique apoptosis
features in bile duct cells has been proposed to explain PBC tissue
speciﬁcity [129]. It was ﬁrst demonstrated that PDC-E2 remains
intact and retains its immunogenicity during cholangiocyte
apoptosis, secondary to a cell-speciﬁc lack of glutathionylation ofFig. 2. A parallel comparison of the proposed immunopathogenesis of PBC and SS. In both c
salivary or biliary epithelial cell apoptosis and contribute to tolerance breakdown to self
translational modiﬁcation (PDC-E2). Salivary and biliary epithelial cells concur to the autoi
Please cite this article in press as: Selmi C, et al., Primary biliary cirrhosi
immunity (2011), doi:10.1016/j.jaut.2011.11.005biliaryepithelial cells [130]. The intact PDC-E2 in apoptotic blebs (i.e.
apotopes) could be then uptaken by local antigen presenting cells
and transferred to regional lymph nodes for priming of cognate T
cells thus initiating PBC [131,132]. Second, biliary epithelial cells are
immunologically active because they express HLA antigens, adhe-
sion and costimulatory molecules, such as LFA3, CD40, CD80, CD86,
cytokines such as IL6, IL8, chemokines, such as MCP1, and growth
factors such as TGF, CTGF, PDGF, endothelin [133,134]. Third, chol-
angiocytes can secrete secretory IgA in the biliary tree [22,135] with
enormous potential implications for PBC pathogenesis as secretory
IgA are important effectors in mucosal immunity. IgA derived from
local plasma cells are internalized into the epithelial cells as
complexes with poly-Ig-receptor, transported to the apical surface
of the cell, through a process called transcytosis, and secreted at the
mucosal surface after poly-Ig-receptor cleavage. IgA AMAhave been
detected not only in the bile, but also in the saliva and urine of
patients [21,136]. More importantly, it has been demonstrated that
IgA AMA are locally produced supporting the hypothesis that other
epithelial tissues other than cholangiocytes are involved in PBC.
Whether IgA antimitochondrial producing immunocytes are
primed in situ or have emigrated from otherMALT is unclear but the
acquired association between PBC and recurrent urinary tract
infections is particularly fascinating [137].Wemay hypothesize that
bacterial derived mitochondrial antigens in the urinary tract may
induce B lymphocyte differentiation into IgA producing plasma cells
within uroepithelium. Finally, the salivary gland ducts of patients
with PBC, independent of the presence of sicca symptoms,manifests
a PBC-like immunohistochemical staining with a monoclonalonditions, environmental triggers (putatively infectious agents and xenobiotics) cause
-antigens exposed on the apoptotic blebs (SSA and SSB) and not protected by post-
mmune process also by expressing cytokines, HLA class II and adhesion molecules.
s and Sjögren’s syndrome: Autoimmune epithelitis, Journal of Auto-
Table 5
Immunological factors involved in the pathogenesis of PBC and SS.
PBC SS
Breaking
tolerance
trigger
Proposed involvement
of infections (E. coli,
N aromaticivorans), xenobiotics
Proposed involvement
of viral infection
(EBV, CMV, retroviruses)
Self-antigen
presentation
Lack of gluthationylation
of PDC-E2 during apoptosis
Exposure of SSA/SSB on
apoptotic blebs and on
exosomes; lack of
gluthationylation of
PDC-E2 during apoptosis
Cellular
immune
response
Granuloma and predominance
of CD4þ inﬁltrate around
bile duct
Predominance of CD4þ
inﬁltrate around
salivary duct
Humoral
immune
response
Epithelial transcytosis of IgA
against self-antigen with locally
production of AMA in bile, saliva,
urine; serum reactivity against
PDE2 from cholangiocyte
and salivary duct epithelia;
disease-speciﬁc
autoantibodies (AMA)
Epithelial transcytosis
of IgA against
self-antigen; B cell
activation with increased
lymphoma risk; not
disease-speciﬁc
autoantibodies
(anti-SSA/SSB,
rheumatoid factor)
C. Selmi et al. / Journal of Autoimmunity xxx (2011) 1e96antimitochondrial antibody speciﬁc for the self-antigen PDC-E2
[138], further supporting the proposed locally driven autoimmune
epithelitis. Finally, we cannot rule out that, similar towhat has been
reported in multiple sclerosis, post-translational modiﬁcations of
self-antigens may also play a role in PBC tolerance breakdown [139]
as new mechanisms are being proposed for SS [140e142].
8. Treatment
Different from SS in which new treatments are being tested
[143e145], the only approved treatment for PBC remains urso-
deoxycholic acid (UDCA) at recommended doses of 13e15 mg/kg
[23,63]. The mechanism of action of UDCA in PBC is incompletely
understood but it has been hypothesized that it is based on
different factors, including modiﬁcation of the bile acid pool,
reduction in proinﬂammatory cytokines, effects on apoptosis and
on vasoactive mediators [146]. A meta-analysis demonstrated that
an increased survival is only obtained when a dose > 13 mg/kg is
prescribed [147,148], despite the fact that a complete biochemical
response to UDCA (i.e. normalization of alkaline phosphatase) is
achieved in approximately 50% of treated patients. Importantly,
none of the medical treatments currently used for SS are contra-
indicated in patients with coexisting PBC.
Nevertheless, immunosuppressive drugs have also been used in
PBC with poor efﬁcacy, including corticosteroids, azathioprine,
cyclosporine, methotrexate, penicillamine, and colchicine. Liver
transplantation is the ultimate treatment for end-stage PBC but
recurrence is common and its rates seem to be inﬂuenced by
certain immunosuppressive regimens, while the use of UDCA for
recurrence is safe and recommended.Table 6
Proposed animal models for PBC and SS.
PBC [157] SS [158]
NOD.c3c4 Aec1Aec2
dnTGFbRII NOD.B10-H2b
IL-2Ra/ FS/sld
Ae2(a.b)-deﬁcient IQI/Jic
Xenobiotic on C57BL/6 CAII immunization
N. aromaticivorans on NOD 1101 PI3 K Knock-out
ID3 Knock-out
Ar Knock-out
Ro immunization
Aly/aly
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immunity (2011), doi:10.1016/j.jaut.2011.11.0059. Conclusions
We speculate that PBC is a classic phenotype of autoimmune
epithelitis and this thesis applies to salivary glands and, of course, SS.
There are also major differences between SS and PBC and these
include the genetic bases of disease susceptibility as well as other
mechanismswell illustrated by the available animalmodels (Table 6).
The recently completed genome-wide association studies performed
reported a signiﬁcant association of PBCwith polymorphisms of HLA,
IL12A, IL12RB2, and to a minor extent, STAT4 [101,102] while data on
SS can only be gathered from those in lupus [149] andmanifest some
degree of similarity with PBC in the minor STAT4 association.
Importantly, based on the biology of the target epithelium, there
likely are common effector mechanisms. Dissection of these effector
mechanisms will become important in any therapeutics. Finally, we
submit that PBC and SS comorbidity may identify an intriguing
subgroup of patients inwhich common traits should be investigated.
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